Literature DB >> 2674558

The role of cytokines in the immunopathology of tuberculosis, and the regulation of agalactosyl IgG.

G A Rook1, R A Attiyah, N Foley.   

Abstract

Tuberculosis is characterised by necrosis in the lesions and in skin-test sites, and by fever and weight loss. In contrast, other diseases with chronic T cell mediated responses, such as uncomplicated leprosy and sarcoidosis, have non-necrotising lesions with little systemic upset. Crude sonicates of M. tuberculosis and M. leprae prepare skin sites for TNF-mediated damage via a pathway which unexpectedly appears to involve CD8+ T cells, and both mycobacteria contain potent triggers of TNF release (lipoarabinomannan and peptidoglycan derivatives). These observations can partially explain the pathology of tuberculosis, but fail to explain why similar events do not normally occur in leprosy. It now seems likely that the answer lies in the existence of novel regulatory pathways. A recently recognised correlate (or consequence) of diseases characterised by T cell-dependent tissue-damaging pathology and cytokine release, is an increase in the level of agalactosyl IgG. This behaves like a T cell-dependent acute phase reactant, and is raised in tuberculosis, rheumatoid arthritis, and Crohn's disease, but not in sarcoidosis or uncomplicated leprosy. Thus it may act as a marker for a type of pathology of very broad significance, though its functional role remains obscure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674558

Source DB:  PubMed          Journal:  Lymphokine Res        ISSN: 0277-6766


  12 in total

Review 1.  Model for immune responses to Mycobacterium avium subspecies paratuberculosis in cattle.

Authors:  Paul M Coussens
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Cytokine gene expression in peripheral blood mononuclear cells and tissues of cattle infected with Mycobacterium avium subsp. paratuberculosis: evidence for an inherent proinflammatory gene expression pattern.

Authors:  Paul M Coussens; Nitin Verman; Marc A Coussens; Michael D Elftman; Amanda M McNulty
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 3.  Evaluation of TNF as antiviral, antibacterial and antiparasitic agent.

Authors:  G A Rook; J Taverne; J H Playfair
Journal:  Biotherapy       Date:  1991

4.  An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease.

Authors:  N Foley; C Lambert; M McNicol; N Johnson; G A Rook
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

5.  Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.

Authors:  A Glatman-Freedman; A J Mednick; N Lendvai; A Casadevall
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

6.  Evidence for a novel gene expression program in peripheral blood mononuclear cells from Mycobacterium avium subsp. paratuberculosis-infected cattle.

Authors:  Paul M Coussens; Christopher J Colvin; Guilherme J M Rosa; Juliana Perez Laspiur; Michael D Elftman
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

7.  Serum TNF-alpha, sCD8 and sIL-2R levels in childhood tuberculosis.

Authors:  I B Barlan; M M Başaran; M Bakir; F Tükenmez; N Bekiroğlu
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

8.  Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages.

Authors:  L E Bermudez; M Wu; M Petrofsky; L S Young
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

9.  Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system.

Authors:  L Tsenova; A Bergtold; V H Freedman; R A Young; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration.

Authors:  E Jirillo; M Altamura; C Marcuccio; C Tortorella; C De Simone; S Antonaci
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.